Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Coherus Oncology Q3 2026 Results: Net Loss of $39.3M, Loss Widens

Coherus Oncology, Inc. reported 154,538,277 shares of common stock outstanding as of October 31, 2026. The company expressed substantial doubt about its ability to continue as a going concern due to expected future operating losses and negative cash flows, following the divestiture of its UDENYCA franchise.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue14.311.6
Profit before tax-38.9-44.5
Net income-39.3-35.5
EPS (diluted, $ a share)$-0.25$-0.31

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+23.4%
Operating margin-235.7%
Source

10-Q filed with the SEC, NASDAQ: CHRS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Coherus Oncology, Inc.: key numbers

Share price
$0.4785Close, Nov 17
Market cap
$73.9M
Shares outstanding
154.54MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Coherus Oncology, Inc.

All →
4:21 PM ET 8-K
Financial Results

Coherus Oncology Financial Results

Coherus Oncology reported Q3 2026 financial results, highlighted by $14.0 million in LOQTORZI net revenue. The company also announced a strategic prioritization plan focusing on tagmokitug for esophageal cancer and a 30% headcount reduction to lower quarterly cash burn.

Term
Q3 2026

“The strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down and the toripalimab process transfer completion, provides an ideal opportunity to right-size the organization and deliver financial benefits that flow directly from this prioritization”

Dennis M. Lanfear, Chief Executive Officer

“The financial benefits of right-sizing the organization and reducing the scope of our forward-focused efforts provide substantial and durable benefits to our operating model”

Bryan McMichael, Chief Financial Officer
8:10 AM ET 8-K
Clinical Trial Data

Coherus Oncology Clinical Trial Data

Coherus Oncology announced interim clinical data from its TREGCHECK program evaluating tagmokitug, a cytolytic CCR8 antibody, in combination with toripalimab for esophageal squamous cell carcinoma (ESCC). The study reported a 75% confirmed overall response rate (cORR) in first-line ESCC patients irrespective of PD-L1 status, which increased to 89% following the data cutoff. The results provide clinical proof-of-concept for tagmokitug and support the expansion of enrollment in both first-line and second-line ESCC cohorts.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.